scholarly journals Biologi Molekuler Human Papilloma Virus

2018 ◽  
Vol 11 (1) ◽  
pp. 1
Author(s):  
Maya Savira
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Human Papilloma Virus ◽  
Cancer Cells ◽  
Persistent Infection ◽  
Malignant Disease ◽  
Risk Group ◽  
High Risk Group ◽  
Papilloma Virus ◽  
Carcinogenic Process

Persistent infection of the high-risk group Human Papilloma Virus (hrHPV) has been known to cause cervical cancer.Currently cervical cancer still ranks as the number two of most malignant disease in women. The infection of HPVthat lead to cancer cells to form can be known through the structure of the HPV virus itself and what particles in thevirus play a role in initiating the carcinogenic process of its host cell.

scholarly journals Analysis of risk factors for persistent infection of asymptomatic women with high-risk human papilloma virus

2017 ◽  
Vol 13 (6) ◽  
pp. 1404-1411 ◽  
Author(s):  
Nianmin Shi ◽  
Qiang Lu ◽  
Jiao Zhang ◽  
Li Li ◽  
Junnan Zhang ◽  
...  
Keyword(s):  
Risk Factors ◽  
High Risk ◽  
Human Papilloma Virus ◽  
Persistent Infection ◽  
Papilloma Virus ◽  
Asymptomatic Women

scholarly journals Immune-Related Four-lncRNA Signature for Patients with Cervical Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-15
Author(s):  
Jianfeng Zheng ◽  
Benben Cao ◽  
Xia Zhang ◽  
Zheng Niu ◽  
Jinyi Tong
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Immune Cell ◽  
Risk Group ◽  
Pearson Correlation ◽  
Characteristic Curve ◽  
Risk Groups ◽  
High Risk Group ◽  
Low Risk ◽  
Gynecological Malignancy

Cervical cancer (CC) is a common gynecological malignancy for which prognostic and therapeutic biomarkers are urgently needed. The signature based on immune-related lncRNAs (IRLs) of CC has never been reported. This study is aimed at establishing an IRL signature for patients with CC. A cohort of 326 CC and 21 normal tissue samples with corresponding clinical information was included in this study. Twenty-eight IRLs were collected according to the Pearson correlation analysis between the immune score and lncRNA expression ( p < 0.01 ). Four IRLs (BZRAP1-AS1, EMX2OS, ZNF667-AS1, and CTC-429P9.1) with the most significant prognostic values ( p < 0.05 ) were identified which demonstrated an ability to stratify patients into the low-risk and high-risk groups by developing a risk score model. It was observed that patients in the low-risk group showed longer overall survival (OS) than those in the high-risk group in the training set, valid set, and total set. The area under the curve (AUC) of the receiver operating characteristic curve (ROC curve) for the four-IRL signature in predicting the one-, two-, and three-year survival rates was larger than 0.65. In addition, the low-risk and high-risk groups displayed different immune statuses in GSEA. These IRLs were also significantly correlated with immune cell infiltration. Our results showed that the IRL signature had a prognostic value for CC. Meanwhile, the specific mechanisms of the four IRLs in the development of CC were ascertained preliminarily.

scholarly journals Human Papilloma Virus Types 16/18 Distribution in Invasive Cervical Cancer: An Evidence for Vaccination in Bihar, India

2021 ◽  
pp. 59-68
Author(s):  
Rahul Kumar ◽  
Vinita Trivedi ◽  
Richa Chauhan ◽  
Akhtar Parwez ◽  
Biplab Pal ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Human Papilloma Virus ◽  
Vaccination Program ◽  
Hpv 16 ◽  
Tissue Samples ◽  
Papilloma Virus ◽  
Cancer Tissues ◽  
High Risk Hpv ◽  
Hpv 18

There is high incidence of cervical cancer in Bihar, India. Vaccination for cervical cancer in developed countries has played a crucial role in limiting the incidence rate of cervical cancer worldwide. In consideration of debate on clinical efficacy of Human Papilloma Virus (HPV) vaccine in India, study on the prevalence of high risk HPV 16/18 strains in different regions of the nation becomes very crucial. Few individual states have started vaccination but centralised vaccination program does not exist due to lack of sufficient genotypic study of Human Papilloma Virus in different parts of India. Bihar is the third most populous state of India and HPV 16/18 distribution has not been reported yet. The nationwide data of HPV 16/18will help to develop a unified centralised vaccination program. We carried out a distribution study of high risk HPV type 16 and 18 in cervical cancer patients attending a tertiary care hospital of Bihar, India.HPV 16/18 types were analysed in cervical cancer tissues (n = 96) of patients attending the regional cancer hospital of Bihar. Tissue samples were analysed for HPV 16 and HPV 18 using a Real Time PCR technique. The results suggest very high prevalence of HPV 16/18. HPV was identified in all the samples (96/96). About, 74 (77.08%) samples presented with HPV 16 whereas, 16 (16.67%) of the samples presented with HPV 18. 6 Co-infection was presented in 6 (6.25%) of the samples of cervical cancer tissues. HPV 16/18 prevalence is more in the women aged between 41 to 61 years.We report 100% prevalence of HPV16/18 in the cervical cancer tissue samples. A way to minimise this gynaecological concern would be to introduce prophylactic vaccines and early screening in the state of Bihar. The data generated would be crucial in drafting for community screening of HPV. We strongly emphasize the prophylactic HPV Vaccination against HPV 16 to control the alarming rate of cervical cancer in one of the most populous state of India, Bihar.

scholarly journals Extracellular Vesicles from Human Papilloma Virus-Infected Cervical Cancer Cells Enhance HIV-1 Replication in Differentiated U1 Cell Line

Viruses ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 239 ◽  
Author(s):  
Sabina Ranjit ◽  
Sunitha Kodidela ◽  
Namita Sinha ◽  
Subhash Chauhan ◽  
Santosh Kumar
Keyword(s):  
Oxidative Stress ◽  
Cervical Cancer ◽  
Human Papilloma Virus ◽  
Cancer Cells ◽  
Cell Line ◽  
Extracellular Vesicles ◽  
Papilloma Virus ◽  
Cervical Cancer Cells ◽  
Hpv Oncoproteins ◽  
Hiv 1

In the current study, we hypothesized that extracellular vesicles (EVs) secreted from human papilloma virus (HPV)-infected cervical cancer cells exacerbate human immunodeficiency virus (HIV)-1 replication in differentiated U1 cell line through an oxidative stress pathway. To test the hypothesis, we treated an HIV-1-infected macrophage cell line (U1) with HPV-infected Caski cell culture supernatant (CCS). We observed a significant increase in HIV-1 replication, which was associated with an increase in the expression of cytochrome P450 (CYPs 1A1 and 2A6) in the CCS-treated U1 cells. Furthermore, we isolated EVs from CCS (CCS-EVs), which showed the presence of CYPs (1A1, 2A6), superoxide dismutase 1 (SOD1), and HPV oncoproteins HPV16 E6. CCS-EVs when exposed to the U1 cells also significantly increased HIV-1 replication. Treatment of antioxidant, CYP1A1 and CYP2A6 inhibitors, and chemodietary agents with antioxidant properties significantly reduced the CCS and CCS-EVs mediated HIV-1 replication in U1 cells. Altogether, we demonstrate that cervical cancer cells exacerbate HIV-1 replication in differentiated U1 cell line via transferring CYPs and HPV oncoproteins through EVs. We also show that the viral replication occurs via CYP and oxidative stress pathways, and the viral replication is also reduced by chemodietary agents. This study provides important information regarding biological interactions between HPV and HIV-1 via EVs leading to enhanced HIV-1 replication.

Utilization and outcome of systemic chemotherapy for high-risk early-stage cervical cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e17521-e17521
Author(s):  
Munetaka Takekuma ◽  
Shinya Matsuzaki ◽  
Koji Matsuo
Keyword(s):  
Cervical Cancer ◽  
High Risk ◽  
Systemic Chemotherapy ◽  
Risk Group ◽  
Early Stage ◽  
Nodal Metastasis ◽  
High Risk Group ◽  
Parametrial Invasion ◽  
All Cause Mortality ◽  
Early Stage Cervical Cancer

e17521 Background: To examine trends and outcomes of systemic chemotherapy for high-risk early-stage cervical cancer. Methods: This retrospective observational study queried the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program from 2000-2016. Surgically-treated women with stage T1-2 cervical cancer who had high-risk factors (lymph node metastasis and/or parametrial invasion) and received adjuvant therapy were examined. Propensity score inverse probability of treatment weighting was used to assess the survival estimates for chemotherapy use versus external beam with chemotherapy (CCRT). Results: Among 2, 462 women with high-risk factor, 185 (7.5%) received systemic chemotherapy. Utilization of chemotherapy has significantly increased over time in multivariable analysis (adjusted-odds ratio per 1-year increment, 1.06, 95% confidence interval [CI] 1.02-1.09). In weighted models, adjuvant chemotherapy and CCRT had comparable survival among women aged < 40 (hazard ratio [HR] for all-cause mortality 0.73, 95%CI 0.41-1.33), adenocarcinoma or adenosquamous histologies (HR 0.90, 95%CI 0.62-1.32), and high-risk group based on nodal metastasis alone (HR 1.17, 95%CI 0.84-1.62). In contrast, chemotherapy was associated with increased all-cause mortality compared to CCRT among women aged ≥40 (HR 1.57, 95%CI 1.19-2.06), squamous histology (HR 1.63, 95%CI 1.19-2.22), and high-risk group per parametrial invasion alone (HR 1.87, 95%CI 1.09-3.20) or parametrial invasion with nodal metastasis (HR 1.64, 95%CI 1.06-2.52). Conclusions: Utilization of systemic chemotherapy for high-risk early-stage cervical cancer is increasing in the United States. Survival effects of adjuvant chemotherapy varied per patient and tumor factors, and this indication may be limited to those who are < 40 years with non-squamous histology and absence of parametrial invasion.

Sign in / Sign up

Export Citation Format

Share Document